Literature DB >> 12967343

GH is a positive regulator of tumor necrosis factor alpha-induced adipose related protein in 3T3-L1 adipocytes.

M Fasshauer1, J Klein, S Krahlisch, U Lössner, M Klier, M Blüher, R Paschke.   

Abstract

Tumor necrosis factor (TNF) alpha-induced adipose-related protein (TIARP) has recently been cloned as a TNFalpha-stimulated protein expressed in adipocytes. Its expression is differentiation-dependent and potentially involved in mediating TNFalpha-induced insulin resistance. To further characterize regulation of TIARP gene expression, 3T3-L1 adipocytes were treated with key hormones modulating insulin sensitivity and influencing adipocyte metabolism, and TIARP gene expression was determined by quantitative real-time RT-PCR. Interestingly, TIARP mRNA expression was stimulated almost 9-fold after 500 ng/ml GH were added for 16 h whereas addition of 10 microM isoproterenol, 100 nM insulin and 100 nM dexamethasone for 16 h significantly decreased TIARP gene expression to between 35 and 50% of control levels. In contrast, angiotensin 2 (10 microM) and triiodothyronine (1 microM) did not have any effect. The stimulatory effect of GH was time- and dose-dependent with stimulation occurring as early as 1 h after effector addition and at concentrations as low as 5 ng/ml GH. Moreover, pharmacological inhibition of Janus kinase 2 and p42/44 mitogen-activated protein kinase reversed the stimulatory effect of GH, suggesting that both signaling molecules are involved in activation of TIARP gene expression by GH. Furthermore, an increase of TIARP mRNA could be completely reversed to control levels by withdrawal of GH for 24 h. Taken together, these results show that TIARP is not only responsive to TNFalpha but also to important other hormones influencing glucose homeostasis and adipocyte metabolism. Thus, this factor may play an integrative role in the pathogenesis of insulin resistance and its link to obesity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967343     DOI: 10.1677/joe.0.1780523

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

Review 1.  The obesity of bone.

Authors:  Emanuela A Greco; Andrea Lenzi; Silvia Migliaccio
Journal:  Ther Adv Endocrinol Metab       Date:  2015-12       Impact factor: 3.565

2.  [Expressions of inflammatory and fibrogenic factors in perinephric and subcutaneous adipose tissues of patients with adrenocorticotropic hormone-independent Cushing's syndrome].

Authors:  Chun-Yan Wu; Hui-Jian Zhang; Cun-Xia Fan; Peng Wu; Qiang Wei; Ying-Ying Cai; Shao-Zhou Zou; Ling Wang; Yao-Ming Xue; Mei-Ping Guan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

Review 3.  STEAP4: its emerging role in metabolism and homeostasis of cellular iron and copper.

Authors:  Rachel T Scarl; C Martin Lawrence; Hannah M Gordon; Craig S Nunemaker
Journal:  J Endocrinol       Date:  2017-06-02       Impact factor: 4.286

4.  Murine double minute 2 aggravates adipose tissue dysfunction through ubiquitin-mediated six-transmembrane epithelial antigen of prostate 4 degradation.

Authors:  Wei Zhao; Qiang Xu; Jiahui Yang; Xianghong Xie; Chunmei Li; Weihong Zhang; Enhui Chen; Yanfang Guo; Mingyue Gao; Jie Shi; Huabing Zhang; Hong Yao; Meixia Li; Li Yan; Fude Fang; Wenming Wu; Xiaojun Liu
Journal:  iScience       Date:  2022-06-07

Review 5.  STEAP4 and insulin resistance.

Authors:  Xiaoling Chen; Zhiqing Huang; Bo Zhou; Huan Wang; Gang Jia; Guangmang Liu; Hua Zhao
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

6.  Antiobesity Effects of the Ethanol Extract of Laminaria japonica Areshoung in High-Fat-Diet-Induced Obese Rat.

Authors:  Woong Sun Jang; Se Young Choung
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-10       Impact factor: 2.629

7.  STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo.

Authors:  Torstein Lindstad; Su Qu; Jørgen Sikkeland; Yang Jin; Alexandr Kristian; Gunhild M Mælandsmo; Philippe Collas; Fahri Saatcioglu
Journal:  Oncotarget       Date:  2016-08-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.